Klarissa Hanja Stürner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Klarissa Hanja Stürner has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
Christoph Heesen
Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8 shared publications- Christoph Heesen
Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
5 shared publications Jan-Patrick Stellmann
Institute for Neuroimmunology and Clinical MS Research, University Medical Center Hamburg-Eppendorf, Germany
5 shared publications- Clint Hansen
Department of Neurology, University Hospital Schleswig-Holstein and Kiel University, Kiel, Germany
4 shared publications - Jan-Patrick Stellmann
APHM, Hopital de la Timone, CEMEREM 13005 Marseille, France; Aix Marseille Université, CRMBM, CNRS UMR 7339 13385 Marseille, France
4 shared publications - Ole Pless
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany
4 shared publications
Latest Publications
- Open Access
Stability-related foot placement control relies more on mediolateral center-of-mass velocity feedback in people with early Multiple Sclerosis
Impaired gait performance and stability is a key symptom often defining disease outcome in people with Multiple Sclerosis. Step-by-step foot placement control in response to variations in the center-of-mass kinematic state is a crucial gait stability mechanism, especially in the mediolateral direction. Even though it is known that people with Multiple Sclerosis are at an increased risk of falling, step-by-step foot placement control remains to be characterized in this population. Here, we explored characteristic foot placement control in ten people with early stage Multiple Sclerosis, compared to 21 controls walking at a similar average gait speed, during 1-minute steady-state treadmill walking. Kinematic data were analyzed using a linear feedback model that correlated foot placement with the center-of-mass kinematic state during the preceding swing phase. People with Multiple Sclerosis demonstrated step-by-step foot placement control in both the mediolateral and anteroposterior directions. No differences were found in foot placement precision between groups. However, foot placement responses to variations in center-of-mass velocity proved stronger in people with Multiple Sclerosis. Moreover, the contribution of mediolateral center-of-mass velocity feedback to the control mechanism was higher in people with Multiple Sclerosis as compared to neurologically healthy controls. Our results suggest that foot placement control is still retained in early clinically evident stages of Multiple Sclerosis, but is realized through differently weighted sensory feedback control.
Open AccessStability-related foot placement control relies more on mediolateral center-of-mass velocity feedback in people with early Multiple Sclerosis
Impaired gait performance and stability is a key symptom often defining disease outcome in people with Multiple Sclerosis. Step-by-step foot placement control in response to variations in the center-of-mass kinematic state is a crucial gait stability mechanism, especially in the mediolateral direction. Even though it is known that people with Multiple Sclerosis are at an increased risk of falling, step-by-step foot placement control remains to be characterized in this population. Here, we explored characteristic foot placement control in ten people with early stage Multiple Sclerosis, compared to 21 controls walking at a similar average gait speed, during 1-minute steady-state treadmill walking. Kinematic data were analyzed using a linear feedback model that correlated foot placement with the center-of-mass kinematic state during the preceding swing phase. People with Multiple Sclerosis demonstrated step-by-step foot placement control in both the mediolateral and anteroposterior directions. No differences were found in foot placement precision between groups. However, foot placement responses to variations in center-of-mass velocity proved stronger in people with Multiple Sclerosis. Moreover, the contribution of mediolateral center-of-mass velocity feedback to the control mechanism was higher in people with Multiple Sclerosis as compared to neurologically healthy controls. Our results suggest that foot placement control is still retained in early clinically evident stages of Multiple Sclerosis, but is realized through differently weighted sensory feedback control.
- Open Access
- 2 August 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (13) , 1431-1446
Testing the construct validity of real-world digital mobility outcomes in multiple sclerosis
Background: Wearable devices can measure real-world mobility and generate metrics known as digital mobility outcomes (DMOs). For people with multiple sclerosis (pwMS), these DMOs have not been clinically validated. This study aimed to evaluate the construct (convergent, divergent, and known groups) validity of a comprehensive panel of 24 DMOs in pwMS. Methods: PwMS were recruited to the Mobilise-D Clinical Validation Study, which involved 7-days of real-world mobility monitoring with a lower-back-worn wearable device. DMOs of walking amount, pattern, pace, rhythm, and variability domains were assessed. Convergent validity was evaluated against established clinical constructs (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk, Multiple sclerosis (MS) Walking Scale-12, and Patient-Determined Disease Steps) using a priori hypotheses. Divergent validity was tested against systolic blood pressure. Known-groups validity was assessed across three EDSS strata. An expert panel completed a standardised consensus process. Results: We included 556 participants: 65% women, mean (SD) age of 52.3 (10.7) years, and median (p25–p75) EDSS 5 (4–6). Convergent, divergent, and known-groups validity were supported for 19, 24, and 23 DMOs, respectively. Nineteen DMOs, covering all domains, reached consensus agreement. Conclusion: This study confirms the construct validity of 19 DMOs across all walking domains in pwMS, supporting their use in clinical research and practice. www.isrctn.com/ISRCTN12051706 .
- 2 August 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (13) , 1431-1446
Open AccessTesting the construct validity of real-world digital mobility outcomes in multiple sclerosis
Background: Wearable devices can measure real-world mobility and generate metrics known as digital mobility outcomes (DMOs). For people with multiple sclerosis (pwMS), these DMOs have not been clinically validated. This study aimed to evaluate the construct (convergent, divergent, and known groups) validity of a comprehensive panel of 24 DMOs in pwMS. Methods: PwMS were recruited to the Mobilise-D Clinical Validation Study, which involved 7-days of real-world mobility monitoring with a lower-back-worn wearable device. DMOs of walking amount, pattern, pace, rhythm, and variability domains were assessed. Convergent validity was evaluated against established clinical constructs (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk, Multiple sclerosis (MS) Walking Scale-12, and Patient-Determined Disease Steps) using a priori hypotheses. Divergent validity was tested against systolic blood pressure. Known-groups validity was assessed across three EDSS strata. An expert panel completed a standardised consensus process. Results: We included 556 participants: 65% women, mean (SD) age of 52.3 (10.7) years, and median (p25–p75) EDSS 5 (4–6). Convergent, divergent, and known-groups validity were supported for 19, 24, and 23 DMOs, respectively. Nineteen DMOs, covering all domains, reached consensus agreement. Conclusion: This study confirms the construct validity of 19 DMOs across all walking domains in pwMS, supporting their use in clinical research and practice. www.isrctn.com/ISRCTN12051706 .
- Open Access
- 14 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (3)
Cross-platform comparison of blood glial fibrillary acidic protein quantification in healthy controls and multiple sclerosis
Background: Glial fibrillary acidic protein (GFAP) is an astrocyte marker increasingly recognized as a biomarker of disease progression in multiple sclerosis (MS). While highly sensitive assays are available, cross-platform harmonization remains insufficient, limiting routine clinical implementation. Objective: To compare three fully automated GFAP assays, assess their analytical agreement and clinical performance across MS subtypes and healthy controls, and evaluate cross-platform conversion approaches. Methods: Serum samples from 435 individuals (298 healthy controls, 51 relapsing–remitting MS (RRMS), 41 primary/secondary progressive MS (PPMS/SPMS)) were analyzed using three automated platforms: Simoa HD-X (Quanterix), Elecsys (Roche), and Lumipulse G600 (Fujirebio). Correlation analyses, Passing–Bablok regression, and Lin's concordance coefficients were applied. Published regression formulas were compared with study-derived equations. Results: Strong correlations were observed across all platforms ( r > 0.90 with outliers; r > 0.95 without; p < 0.001), though minor systematic biases were detected. Progressive MS patients showed significantly higher GFAP concentrations than RRMS and controls. Conversion to a single-platform scale improved agreement, but regression formulas differed substantially from previously published equations. Conclusion: Serum GFAP measurements demonstrate high clinical comparability across automated platforms despite systematic differences in absolute values. Robust harmonization strategies and externally validated conversion models are required before broad implementation in routine MS diagnostics.
- 14 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (3)
Open AccessCross-platform comparison of blood glial fibrillary acidic protein quantification in healthy controls and multiple sclerosis
Background: Glial fibrillary acidic protein (GFAP) is an astrocyte marker increasingly recognized as a biomarker of disease progression in multiple sclerosis (MS). While highly sensitive assays are available, cross-platform harmonization remains insufficient, limiting routine clinical implementation. Objective: To compare three fully automated GFAP assays, assess their analytical agreement and clinical performance across MS subtypes and healthy controls, and evaluate cross-platform conversion approaches. Methods: Serum samples from 435 individuals (298 healthy controls, 51 relapsing–remitting MS (RRMS), 41 primary/secondary progressive MS (PPMS/SPMS)) were analyzed using three automated platforms: Simoa HD-X (Quanterix), Elecsys (Roche), and Lumipulse G600 (Fujirebio). Correlation analyses, Passing–Bablok regression, and Lin's concordance coefficients were applied. Published regression formulas were compared with study-derived equations. Results: Strong correlations were observed across all platforms ( r > 0.90 with outliers; r > 0.95 without; p < 0.001), though minor systematic biases were detected. Progressive MS patients showed significantly higher GFAP concentrations than RRMS and controls. Conversion to a single-platform scale improved agreement, but regression formulas differed substantially from previously published equations. Conclusion: Serum GFAP measurements demonstrate high clinical comparability across automated platforms despite systematic differences in absolute values. Robust harmonization strategies and externally validated conversion models are required before broad implementation in routine MS diagnostics.
- Open Access
- 12 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (10) , 1231-1242
Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial
Background: This randomised controlled trial investigated the effect of a personalised digital lifestyle management application (‘levidex’) on inflammatory disease activity in newly diagnosed people with MS (pwMS), compared to a non-personalised application (‘dexilev’) that covered similar lifestyle-related content. Methods: Participants ( N = 234) were recruited from July 2019 to April 2022 in 20 study centres in Germany and randomised to levidex (intervention group (IG), n = 115) or ‘dexilev’ (control group (CG), n = 119). Follow-up data was collected over 1-2 years. The combined primary endpoint (new T2 lesion and/or relapse) was analysed using Cox proportional hazards regression. Key secondary endpoints included self-reported quality of life and health behaviour. Results: There was no difference in the time to the first relapse and/or new T2 lesion between IG and CG (Hazard Ratio: 0.91; 95% confidence interval [CI]: [0.66, 1.27], p = 0.596). After 3 months, self-reported diet quality was higher in the IG (0.43; 95% CI: [0.14, 0.72], p = 0.0037). There was no difference in other secondary endpoints between IG and CG after 3 and 12 months. Conclusions: This study failed to meet its primary endpoint and usage of levidex did not differ from dexilev in its effects on inflammatory disease activity or behaviour change in this cohort of pwMS.
- 12 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (10) , 1231-1242
Open AccessDigital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial
Background: This randomised controlled trial investigated the effect of a personalised digital lifestyle management application (‘levidex’) on inflammatory disease activity in newly diagnosed people with MS (pwMS), compared to a non-personalised application (‘dexilev’) that covered similar lifestyle-related content. Methods: Participants ( N = 234) were recruited from July 2019 to April 2022 in 20 study centres in Germany and randomised to levidex (intervention group (IG), n = 115) or ‘dexilev’ (control group (CG), n = 119). Follow-up data was collected over 1-2 years. The combined primary endpoint (new T2 lesion and/or relapse) was analysed using Cox proportional hazards regression. Key secondary endpoints included self-reported quality of life and health behaviour. Results: There was no difference in the time to the first relapse and/or new T2 lesion between IG and CG (Hazard Ratio: 0.91; 95% confidence interval [CI]: [0.66, 1.27], p = 0.596). After 3 months, self-reported diet quality was higher in the IG (0.43; 95% CI: [0.14, 0.72], p = 0.0037). There was no difference in other secondary endpoints between IG and CG after 3 and 12 months. Conclusions: This study failed to meet its primary endpoint and usage of levidex did not differ from dexilev in its effects on inflammatory disease activity or behaviour change in this cohort of pwMS.
- Open Access
- 30 March 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e41082
Turning When Using Smartphone in Persons With and Those Without Neurologic Conditions: Observational Study
Background: Turning during walking is a relevant and common everyday movement and it depends on a correct top-down intersegmental coordination. This could be reduced in several conditions (en bloc turning), and an altered turning kinematics has been linked to increased risk of falls. Smartphone use has been associated with poorer balance and gait; however, its effect on turning-while-walking has not been investigated yet. This study explores turning intersegmental coordination during smartphone use in different age groups and neurologic conditions. Objective: This study aims to evaluate the effect of smartphone use on turning behavior in healthy individuals of different ages and those with various neurological diseases. Methods: Younger (aged 18-60 years) and older (aged >60 years) healthy individuals and those with Parkinson disease, multiple sclerosis, subacute stroke (<4 weeks), or lower-back pain performed turning-while-walking alone (single task [ST]) and while performing 2 different cognitive tasks of increasing complexity (dual task [DT]). The mobility task consisted of walking up and down a 5-m walkway at self-selected speed, thus including 180° turns. Cognitive tasks consisted of a simple reaction time test (simple DT [SDT]) and a numerical Stroop test (complex DT [CDT]). General (turn duration and the number of steps while turning), segmental (peak angular velocity), and intersegmental turning parameters (intersegmental turning onset latency and maximum intersegmental angle) were extracted for head, sternum, and pelvis using a motion capture system and a turning detection algorithm. Results: In total, 121 participants were enrolled. All participants, irrespective of age and neurologic disease, showed a reduced intersegmental turning onset latency and a reduced maximum intersegmental angle of both pelvis and sternum relative to head, thus indicating an en bloc turning behavior when using a smartphone. With regard to change from the ST to turning when using a smartphone, participants with Parkinson disease reduced their peak angular velocity the most, which was significantly different from lower-back pain relative to the head (P<.01). Participants with stroke showed en bloc turning already without smartphone use. Conclusions: Smartphone use during turning-while-walking may lead to en bloc turning and thus increase fall risk across age and neurologic disease groups. This behavior is probably particularly dangerous for those groups with the most pronounced changes in turning parameters during smartphone use and the highest fall risk, such as individuals with Parkinson disease. Moreover, the experimental paradigm presented here might be useful in differentiating individuals with lower-back pain without and those with early or prodromal Parkinson disease. In individuals with subacute stroke, en bloc turning could represent a compensative strategy to overcome the newly occurring mobility deficit. Considering the ubiquitous smartphone use in daily life, this study should stimulate future studies in the area of fall risk and neurological and orthopedic diseases. Trial Registration: German Clinical Trials Register DRKS00022998; https://drks.de/search/en/trial/DRKS00022998
- 30 March 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e41082
Open AccessTurning When Using Smartphone in Persons With and Those Without Neurologic Conditions: Observational Study
Background: Turning during walking is a relevant and common everyday movement and it depends on a correct top-down intersegmental coordination. This could be reduced in several conditions (en bloc turning), and an altered turning kinematics has been linked to increased risk of falls. Smartphone use has been associated with poorer balance and gait; however, its effect on turning-while-walking has not been investigated yet. This study explores turning intersegmental coordination during smartphone use in different age groups and neurologic conditions. Objective: This study aims to evaluate the effect of smartphone use on turning behavior in healthy individuals of different ages and those with various neurological diseases. Methods: Younger (aged 18-60 years) and older (aged >60 years) healthy individuals and those with Parkinson disease, multiple sclerosis, subacute stroke (<4 weeks), or lower-back pain performed turning-while-walking alone (single task [ST]) and while performing 2 different cognitive tasks of increasing complexity (dual task [DT]). The mobility task consisted of walking up and down a 5-m walkway at self-selected speed, thus including 180° turns. Cognitive tasks consisted of a simple reaction time test (simple DT [SDT]) and a numerical Stroop test (complex DT [CDT]). General (turn duration and the number of steps while turning), segmental (peak angular velocity), and intersegmental turning parameters (intersegmental turning onset latency and maximum intersegmental angle) were extracted for head, sternum, and pelvis using a motion capture system and a turning detection algorithm. Results: In total, 121 participants were enrolled. All participants, irrespective of age and neurologic disease, showed a reduced intersegmental turning onset latency and a reduced maximum intersegmental angle of both pelvis and sternum relative to head, thus indicating an en bloc turning behavior when using a smartphone. With regard to change from the ST to turning when using a smartphone, participants with Parkinson disease reduced their peak angular velocity the most, which was significantly different from lower-back pain relative to the head (P<.01). Participants with stroke showed en bloc turning already without smartphone use. Conclusions: Smartphone use during turning-while-walking may lead to en bloc turning and thus increase fall risk across age and neurologic disease groups. This behavior is probably particularly dangerous for those groups with the most pronounced changes in turning parameters during smartphone use and the highest fall risk, such as individuals with Parkinson disease. Moreover, the experimental paradigm presented here might be useful in differentiating individuals with lower-back pain without and those with early or prodromal Parkinson disease. In individuals with subacute stroke, en bloc turning could represent a compensative strategy to overcome the newly occurring mobility deficit. Considering the ubiquitous smartphone use in daily life, this study should stimulate future studies in the area of fall risk and neurological and orthopedic diseases. Trial Registration: German Clinical Trials Register DRKS00022998; https://drks.de/search/en/trial/DRKS00022998
- Open Access
- 14 July 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Turning when using a smartphone in persons with and without neurologic conditions: an observational study (Preprint)
BACKGROUND Turning during walking is a relevant and common everyday movement and it depends on a correct top-down intersegmental coordination. This could be reduced in several conditions (en-bloc turning), and an altered turning kinematics has been linked to increased risk of falls. Smartphone use has been associated with poorer balance and gait, however its effect on turning-while-walking have not been investigated yet. This study explored turning intersegmental coordination when using a smartphone in different age groups and neurologic conditions. OBJECTIVE To evaluate the effect of smartphone use on turning behavior in healthy participants of different ages and patients with various neurological diseases. METHODS Younger (age 18-60 years) and older (age >60 years) healthy participants and patients with Parkinson’s disease (PD), multiple sclerosis, subacute stroke (<4 weeks, SAS) and lower-back pain (LBP) performed turning-while-walking alone (single-task, ST) and while performing two different cognitive tasks of increasing complexity (dual-task, DT). The mobility task consisted of walking up and down a 5-meter walkway at self-selected speed, thus including 180° turns. Cognitive tasks consisted of a simple reaction time test (simple DT, SDT) and a numerical Stroop test (complex DT, CDT). General (turn duration and number of steps while turning), segmental (peak angular velocity) and intersegmental turning parameters (intersegmental turning onset latency and maximum intersegmental angle) were extracted for head, sternum and pelvis using a motion capture system and a turning detection algorithm. RESULTS One hundred twenty-one participants were enrolled. All participants, irrespective of age and neurologic disease, showed a reduced intersegmental turning onset latency and a reduced maximum intersegmental angle of both pelvis and sternum relative to head, thus indicating an en-bloc turning behavior when using a smartphone. Concerning change from ST to turning when using a smartphone, PD patients reduced their peak angular velocity the most, which was significantly different against LBP for head (P<.01). Stroke patients showed an en-bloc turning already without smartphone use. CONCLUSIONS Smartphone use during turning-while-walking may lead to en-bloc turning and thus increase fall risk across age and neurologic disease groups. This behavior is probably particularly dangerous for those groups with most pronounced changes of turning parameters during smartphone use and highest fall risk, such as PD patients. Moreover, the experimental paradigm presented here might be useful in differentiating LBP patients without and with early/prodromal PD. In SAS patients, en-bloc turning could represent a compensative strategy to overcome the newly occurring mobility deficit. Considering the ubiquitous smartphone use in daily life, this study should stimulate future studies in the area of fall risk and neurological as well as orthopedic diseases. CLINICALTRIAL German Clinical Trials Register (https://www.drks.de/drks_web/) DRKS00022998.
- 14 July 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessTurning when using a smartphone in persons with and without neurologic conditions: an observational study (Preprint)
BACKGROUND Turning during walking is a relevant and common everyday movement and it depends on a correct top-down intersegmental coordination. This could be reduced in several conditions (en-bloc turning), and an altered turning kinematics has been linked to increased risk of falls. Smartphone use has been associated with poorer balance and gait, however its effect on turning-while-walking have not been investigated yet. This study explored turning intersegmental coordination when using a smartphone in different age groups and neurologic conditions. OBJECTIVE To evaluate the effect of smartphone use on turning behavior in healthy participants of different ages and patients with various neurological diseases. METHODS Younger (age 18-60 years) and older (age >60 years) healthy participants and patients with Parkinson’s disease (PD), multiple sclerosis, subacute stroke (<4 weeks, SAS) and lower-back pain (LBP) performed turning-while-walking alone (single-task, ST) and while performing two different cognitive tasks of increasing complexity (dual-task, DT). The mobility task consisted of walking up and down a 5-meter walkway at self-selected speed, thus including 180° turns. Cognitive tasks consisted of a simple reaction time test (simple DT, SDT) and a numerical Stroop test (complex DT, CDT). General (turn duration and number of steps while turning), segmental (peak angular velocity) and intersegmental turning parameters (intersegmental turning onset latency and maximum intersegmental angle) were extracted for head, sternum and pelvis using a motion capture system and a turning detection algorithm. RESULTS One hundred twenty-one participants were enrolled. All participants, irrespective of age and neurologic disease, showed a reduced intersegmental turning onset latency and a reduced maximum intersegmental angle of both pelvis and sternum relative to head, thus indicating an en-bloc turning behavior when using a smartphone. Concerning change from ST to turning when using a smartphone, PD patients reduced their peak angular velocity the most, which was significantly different against LBP for head (P<.01). Stroke patients showed an en-bloc turning already without smartphone use. CONCLUSIONS Smartphone use during turning-while-walking may lead to en-bloc turning and thus increase fall risk across age and neurologic disease groups. This behavior is probably particularly dangerous for those groups with most pronounced changes of turning parameters during smartphone use and highest fall risk, such as PD patients. Moreover, the experimental paradigm presented here might be useful in differentiating LBP patients without and with early/prodromal PD. In SAS patients, en-bloc turning could represent a compensative strategy to overcome the newly occurring mobility deficit. Considering the ubiquitous smartphone use in daily life, this study should stimulate future studies in the area of fall risk and neurological as well as orthopedic diseases. CLINICALTRIAL German Clinical Trials Register (https://www.drks.de/drks_web/) DRKS00022998.
- Open Access
Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol
Healthy adults and neurological patients show unique mobility patterns over the course of their lifespan and disease. Quantifying these mobility patterns could support diagnosing, tracking disease progression and measuring response to treatment. This quantification can be done with wearable technology, such as inertial measurement units (IMUs). Before IMUs can be used to quantify mobility, algorithms need to be developed and validated with age and disease-specific datasets. This study proposes a protocol for a dataset that can be used to develop and validate IMU-based mobility algorithms for healthy adults (18–60 years), healthy older adults (>60 years), and patients with Parkinson’s disease, multiple sclerosis, a symptomatic stroke and chronic low back pain. All participants will be measured simultaneously with IMUs and a 3D optical motion capture system while performing standardized mobility tasks and non-standardized activities of daily living. Specific clinical scales and questionnaires will be collected. This study aims at building the largest dataset for the development and validation of IMU-based mobility algorithms for healthy adults and neurological patients. It is anticipated to provide this dataset for further research use and collaboration, with the ultimate goal to bring IMU-based mobility algorithms as quickly as possible into clinical trials and clinical routine.
Open AccessProposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol
Healthy adults and neurological patients show unique mobility patterns over the course of their lifespan and disease. Quantifying these mobility patterns could support diagnosing, tracking disease progression and measuring response to treatment. This quantification can be done with wearable technology, such as inertial measurement units (IMUs). Before IMUs can be used to quantify mobility, algorithms need to be developed and validated with age and disease-specific datasets. This study proposes a protocol for a dataset that can be used to develop and validate IMU-based mobility algorithms for healthy adults (18–60 years), healthy older adults (>60 years), and patients with Parkinson’s disease, multiple sclerosis, a symptomatic stroke and chronic low back pain. All participants will be measured simultaneously with IMUs and a 3D optical motion capture system while performing standardized mobility tasks and non-standardized activities of daily living. Specific clinical scales and questionnaires will be collected. This study aims at building the largest dataset for the development and validation of IMU-based mobility algorithms for healthy adults and neurological patients. It is anticipated to provide this dataset for further research use and collaboration, with the ultimate goal to bring IMU-based mobility algorithms as quickly as possible into clinical trials and clinical routine.
- Open Access
- 29 May 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 8776
Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be affected by frankincense extracts. We performed LM profiling by metabololipidomics in plasma samples from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took a standardised frankincense extract (SFE) daily for eight months in a clinical phase IIa trial (NCT01450124) and in 28 age- and gender-matched healthy controls. Magnetic resonance imaging, immunological outcomes and serum neurofilament light chain levels were correlated to changes in the LM profiles of the RR-MS cohort. Eight out of 44 analysed LMs were significantly reduced during an eight-month treatment period by the SFE and seven of these eight significant LM derive from the 5-lipoxygenase (5-LO) pathway. Baseline levels of 12- and 15-LO products were elevated in patients who exhibited disease activity (EDA) during SFE treatment compared to no-evidence-of-disease-activity (NEDA) patients and could predict treatment response to the SFE in a prediction model at baseline. Oral treatment with an SFE significantly reduces 5-LO-derived LMs in RR-MS patients during an eight-month treatment period. Treatment response to an SFE, however, seems to be related to 12-,15-LO and cyclooxygenase product levels before SFE exposure. Further studies should confirm their biomarker potential in RR-MS and SFE treatment.
- 29 May 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 8776
Open AccessLipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be affected by frankincense extracts. We performed LM profiling by metabololipidomics in plasma samples from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took a standardised frankincense extract (SFE) daily for eight months in a clinical phase IIa trial (NCT01450124) and in 28 age- and gender-matched healthy controls. Magnetic resonance imaging, immunological outcomes and serum neurofilament light chain levels were correlated to changes in the LM profiles of the RR-MS cohort. Eight out of 44 analysed LMs were significantly reduced during an eight-month treatment period by the SFE and seven of these eight significant LM derive from the 5-lipoxygenase (5-LO) pathway. Baseline levels of 12- and 15-LO products were elevated in patients who exhibited disease activity (EDA) during SFE treatment compared to no-evidence-of-disease-activity (NEDA) patients and could predict treatment response to the SFE in a prediction model at baseline. Oral treatment with an SFE significantly reduces 5-LO-derived LMs in RR-MS patients during an eight-month treatment period. Treatment response to an SFE, however, seems to be related to 12-,15-LO and cyclooxygenase product levels before SFE exposure. Further studies should confirm their biomarker potential in RR-MS and SFE treatment.
- 14 November 2019
- Published by Georg Thieme Verlag KG in Osteologie
- Vol. 28 (04) , 259-267
Osteoporose und Frakturen bei Multipler Sklerose – unterschätzt und ignoriert?
Zusammenfassung: Multiple Sklerose (MS) ist eine chronisch entzündliche Autoimmunerkrankung des zentralen Nervensystems mit hoher Prävalenz. Mehrere Studien zeigen die deutlich erhöhte Häufigkeit sowohl von Frakturen als auch einer Osteoporose bei MS-Erkrankten: So besteht ein in mehreren Studien gezeigtes knapp 3-fach erhöhtes Hüftfrakturrisiko bei MS-Patienten, die Prävalenz von Osteopenie und Osteoporoserate ist bis zu 10-fach gegenüber der Normalbevölkerung erhöht. Der deutlichste Zusammenhang besteht zwischen dem Osteoporoserisiko und -ausmaß und dem Grad der Immobilität, aber auch die entzündliche Krankheitspathologie sowie Lebensstilfaktoren wie Vitamin D, Rauchen, sowie hormonelle Dysregulationen, Begleiterkrankungen und Medikamente tragen grundsätzlich und kumulativ zum erhöhten Osteoporose- und Frakturrisiko bei. Das deutlich erhöhte Osteoporose und Frakturrisiko wird im klinischen Alltag von MS-Patienten nur selten thematisiert, obwohl schon früh eine negative Beeinträchtigung des Knochenstoffwechsels vorliegt. Frakturrisiko und Osteoporose sind daher eine bisher unterschätzte Problematik bei MS-Erkrankten, die in einem präventiven Ansatz früh von den Behandlern thematisiert werden sollte. Ausgleich einer Vitamin D-Defizienz und vor allem ein Erhalt der Mobilität sind die am besten durch Daten belegten präventiven Maßnahmen zur Vermeidung einer fortschreitenden Osteoporose und zur Reduktion des Frakturrisikos.
- 14 November 2019
- Published by Georg Thieme Verlag KG in Osteologie
- Vol. 28 (04) , 259-267
Osteoporose und Frakturen bei Multipler Sklerose – unterschätzt und ignoriert?
Zusammenfassung: Multiple Sklerose (MS) ist eine chronisch entzündliche Autoimmunerkrankung des zentralen Nervensystems mit hoher Prävalenz. Mehrere Studien zeigen die deutlich erhöhte Häufigkeit sowohl von Frakturen als auch einer Osteoporose bei MS-Erkrankten: So besteht ein in mehreren Studien gezeigtes knapp 3-fach erhöhtes Hüftfrakturrisiko bei MS-Patienten, die Prävalenz von Osteopenie und Osteoporoserate ist bis zu 10-fach gegenüber der Normalbevölkerung erhöht. Der deutlichste Zusammenhang besteht zwischen dem Osteoporoserisiko und -ausmaß und dem Grad der Immobilität, aber auch die entzündliche Krankheitspathologie sowie Lebensstilfaktoren wie Vitamin D, Rauchen, sowie hormonelle Dysregulationen, Begleiterkrankungen und Medikamente tragen grundsätzlich und kumulativ zum erhöhten Osteoporose- und Frakturrisiko bei. Das deutlich erhöhte Osteoporose und Frakturrisiko wird im klinischen Alltag von MS-Patienten nur selten thematisiert, obwohl schon früh eine negative Beeinträchtigung des Knochenstoffwechsels vorliegt. Frakturrisiko und Osteoporose sind daher eine bisher unterschätzte Problematik bei MS-Erkrankten, die in einem präventiven Ansatz früh von den Behandlern thematisiert werden sollte. Ausgleich einer Vitamin D-Defizienz und vor allem ein Erhalt der Mobilität sind die am besten durch Daten belegten präventiven Maßnahmen zur Vermeidung einer fortschreitenden Osteoporose und zur Reduktion des Frakturrisikos.
- Open Access
- 1 October 2019
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 5 (4)
Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. To assess whether multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. Patients (n = 1230) and healthy controls (n = 2110) were genotyped for HLA-DRB1 and HLA-DRB5. The baseline Expanded Disability Status Scale (EDSS) score was determined and patients were followed for at least 3 years. After follow-up of the consecutive cohort 349 patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA- DRB1*15:01 was the only enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01∼HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score, disease duration and frequency of the category secondary progressive multiple sclerosis with relapse were increased in the HLA-DRB1*15:01∼HLA-DRB5*01:01 positive group. The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and showed weak indirect evidence for a role in progression of the disease.
- 1 October 2019
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 5 (4)
Open AccessIs multiple sclerosis progression associated with the HLA-DR15 haplotype?
The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. To assess whether multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01∼HLA-DRB5*01:01. Patients (n = 1230) and healthy controls (n = 2110) were genotyped for HLA-DRB1 and HLA-DRB5. The baseline Expanded Disability Status Scale (EDSS) score was determined and patients were followed for at least 3 years. After follow-up of the consecutive cohort 349 patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA- DRB1*15:01 was the only enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01∼HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score, disease duration and frequency of the category secondary progressive multiple sclerosis with relapse were increased in the HLA-DRB1*15:01∼HLA-DRB5*01:01 positive group. The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and showed weak indirect evidence for a role in progression of the disease.